Figure 2.
Figure 2. UAE inhibition does not impact upon proteasome function. (A) Accumulation of ubiquitin (Ub)-protein conjugates was evaluated in the indicated cell lines after exposure to TAK-243, bortezomib, or to the combination of the 2 agents at the indicated concentrations for 24 hours. (B) RPMI 8226 and ANBL-6 cells transfected with a vector expressing the ZsGreen-MODC-d410 fusion protein were exposed to TAK-243 or bortezomib at the indicated concentrations. Expression levels of this protein, which is degraded in a proteasome-dependent but ubiquitin-independent manner, were then evaluated by fluorescence monitoring, and the panel shows fluorescence (λex 488 nM/λem 510 nM). (C) MM1.S and U266 cells were then exposed to TAK-243 or bortezomib under the conditions described in panel A, and western blotting was used to determine the abundance of MCL1 and cMYC.

UAE inhibition does not impact upon proteasome function. (A) Accumulation of ubiquitin (Ub)-protein conjugates was evaluated in the indicated cell lines after exposure to TAK-243, bortezomib, or to the combination of the 2 agents at the indicated concentrations for 24 hours. (B) RPMI 8226 and ANBL-6 cells transfected with a vector expressing the ZsGreen-MODC-d410 fusion protein were exposed to TAK-243 or bortezomib at the indicated concentrations. Expression levels of this protein, which is degraded in a proteasome-dependent but ubiquitin-independent manner, were then evaluated by fluorescence monitoring, and the panel shows fluorescence (λex 488 nM/λem 510 nM). (C) MM1.S and U266 cells were then exposed to TAK-243 or bortezomib under the conditions described in panel A, and western blotting was used to determine the abundance of MCL1 and cMYC.

Close Modal

or Create an Account

Close Modal
Close Modal